Background: Suppression of hypothalamic-pituitary-gonadal system activity by luliberin analogues in premature sexual development of the central genesis is accompanied by a decrease in growths velocity, sexual development and progression of bone age.
Aim: Study of the effectiveness of gonadotropin-releasing hormone agonist therapy, their influence on the physical development
Methods: 66 patients were treated by triptorelin. Idiopathic premature sexual development was identified in 40 children, hypothalamic hamartoma - 3, glial tumor - 1, organic central nervous system lesion 15, congenital adrenal hyperplasia 7.
Results: The use of triptorelin once daily for 28 days intramuscularly at a dose of 3.75 mg led to a significant decrease in the growths rate. The growth rate at the 1st year of therapy with analogues of lyuliberin averaged 6.0+1.7 cm/year, which was 1.8 times lower than the growth rate before treatment. In the second year of therapy, the growth rate decreased to 4.5+0.9 cm/year, and after 2 years of treatment, it was 4.3+1.2 cm/year, which is 2.5 times lower than before the start of therapy.
Conclusions: Treatment with analogues of lyuliberin adequately suppresses the activation of the hypothalamic-pituitary-gonadal system, which is accompanied by a decrease in the rate of growth, sexual development and progression of bone age. This leads to an increase in the final growth about 10 cm, compared with untreated patients.
27 - 29 Sep 2018
European Society for Paediatric Endocrinology